Among gliomas, 19/37 (52.6%) cases showed high PTEN expression and 18/37 (48.6%) displayed reduced (5/37; 13.5%) or highly reduced (13/37; 35.1%) immunopositivity (Figure 2A–C). This evidence concerns the gene PTEN and central nervous system cancer.